Wockhardt gets tentative approval for Sumatriptan Succinate
India Pharmaceutical major Wockhardt Limited has informed that it has received tentative approval from the U.S. Food and Drug Administration to make and sell Sumatriptan Succinate in dose of 6 milligram per 0.5 milliliter.
Sumatriptan Succinate is the generic version of GlaxoSmithKline (GSK) Imitrex injection. The drug is prescribed for the treatment of a migraine attack with or without the presence of an aura.
Wockhardt Limited, a pharmaceutical and biotechnology company, together with its subsidiaries, engages in the research, development, and marketing of formulations, biopharmaceuticals, nutrition products, vaccines, and active pharmaceutical ingredients (API) primarily in India, the United States, and Europe.
Presently, many leading stock brokers are advising investors to buy ‘Wockhardt’ scrip at the current levels. According to them, the counter is one of the leaders in its segment and it is poised to give decent returns in coming months.
